Arrowhead Research | ARWR - Operating Expenses



Arrowhead Research reported $193.32M in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
Agios Pharmaceuticals USD 139.51M 24.16M Jun/2025
Alnylam Pharmaceuticals USD 789.89M 213.78M Jun/2025
Arrowhead Research USD 193.32M 31.81M Jun/2025
Incyte USD 904.7M 56.97M Jun/2025
Ionis Pharmaceuticals USD 312.21M 34.21M Jun/2025
Ligand Pharmaceuticals USD 40.46M 41.09M Jun/2025
Merck USD 9.44B 217M Jun/2025
Moderna USD 1.04B 113M Jun/2025
Novartis USD 9.97B 1.02B Jun/2025
Sarepta Therapeutics USD 495.51M 549.73M Jun/2025
TG Therapeutics USD 106.3M 5.93M Jun/2025
Ultragenyx Pharmaceutical USD 274.38M 7.85M Jun/2025
Vertex Pharmaceuticals USD 1.81B 71.4M Jun/2025
Xencor USD 76.78M 865K Jun/2025